The Longevity Fund

Loyal is a biotechnology company focused on developing medicines to extend the lifespan of dogs. By creating drugs that potentially slow aging processes, they aim to delay or prevent age-related diseases such as cancer and dementia.

Edocate develops a medical simulation platform focused on chronic disease management. Its platform enables healthcare professionals to engage with virtual patient cases across various therapeutic areas, providing insights into decision-making processes, clinical gaps, and prescription patterns.

Circumvent Pharmaceuticals Inc. is a biotechnology company based in Portland, Oregon, founded in 2017. The company focuses on researching and developing innovative drugs for neurodegenerative diseases, specifically targeting heritable forms of these conditions. Circumvent aims to address the significant unmet medical needs of patients suffering from both rare and common neurodegenerative disorders, including Batten disease and its variants. By leveraging funding from organizations such as NIH/NINDS and various investment groups, Circumvent is committed to advancing drug discovery and development within the field of precision medicine for neurodegenerative diseases.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

Founded in 2017, Elevian is a biotechnology company dedicated to developing regenerative medicines. It focuses on restoring the body's natural repair mechanisms to prevent and treat age-related diseases such as stroke recovery, Alzheimer's disease, coronary artery disease, and Type 2 diabetes.

Wellth operates a mobile application that engages consumers in managing chronic diseases and fostering healthy habits. By providing targeted incentives, reminders, and information, Wellth aims to reduce healthcare costs by encouraging preventative actions and disease management.

Celevity is a seed-stage company that develops drugs to help dogs live longer, healthier lives. It sees aging as a disease that is able to be slowed and improved with medicines. It was spun out of Laura Deming’s The Longevity Fund. Celevity is headquartered in San Francisco, California.

Loyal is a biotechnology company focused on developing medicines to extend the lifespan of dogs. By creating drugs that potentially slow aging processes, they aim to delay or prevent age-related diseases such as cancer and dementia.

Epirium Bio, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for cardiovascular diseases, metabolic syndrome, and disorders characterized by mitochondrial dysfunction. Founded in 2008, the company leverages unique insights into mitochondrial biology and tissue regeneration to create a small molecule platform aimed at improving muscle strength and facilitating tissue regeneration. Epirium Bio's innovative approach addresses significant clinical needs in treating neuromuscular, neurodegenerative, and mitochondrial disorders, enabling healthcare providers to better support patients suffering from conditions such as muscular dystrophy.

Exo is a medical device startup specializing in handheld ultrasound technology. It combines advanced materials, sensors, signal processing, and computation with semiconductor manufacturing economies to deliver affordable, high-quality imaging. This empowers healthcare professionals to make critical real-time decisions, enhancing patient outcomes.

Deciduous Therapeutics is a biotechnology company focused on developing innovative immune-modulatory therapies aimed at addressing age-related diseases. The company specializes in creating novel molecules that activate the body's natural immune surveillance mechanisms to selectively eliminate senescent cells, which are associated with various age-related conditions. Led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, an experienced biotech entrepreneur, Deciduous Therapeutics is dedicated to promoting a healthier lifespan through its pioneering approach to therapeutics in the aging sector.

Fauna Bio develops a cross-mammal drug discovery platform that leverages biology from hibernating and other non-model animals to identify mechanisms that protect against injury and disease. By integrating genomics, transcriptomics, metabolomics, and proteomics across hundreds of species, the company identifies novel drug targets and advances therapeutics for conditions such as heart attack, stroke, neurodegenerative diseases, and other serious human illnesses. Founded by scientists in 2018, it is based in San Francisco. The approach aims to translate natural protective biology into preclinical and early clinical testing to enable recovery from emergency medical conditions.

Spring Discovery, Inc. is a biotechnology company based in Palo Alto, California, that specializes in the development of a machine learning-based drug discovery platform. This platform is designed to expedite the identification of therapies targeting the biological processes of aging and related diseases. By focusing on the underlying mechanisms of aging, Spring Discovery aims to uncover new treatments for various age-related conditions, including cardiovascular and neurodegenerative diseases. The company's innovative approach seeks to enhance healthy lifespans and improve the quality of life for the aging population.

Gordian Biotechnology is a therapeutics company based in San Francisco, California, founded in 2018. It specializes in developing a unique screening platform aimed at enhancing the efficiency of gene therapy development for complex age-related diseases. The company's platform focuses on researching and creating therapeutic drugs that target premature aging in humans, with the goal of curing age-related conditions and improving skin health.

System1 Biosciences, Inc. is a San Francisco-based neurotherapeutics company established in 2017, specializing in drug discovery for complex neurological and psychiatric disorders, including epilepsy, autism, and schizophrenia. The company employs phenotypic screening, integrating cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to uncover novel characterizations of diseases. This innovative approach allows System1 to identify "deep phenotypes," which are utilized to discover new therapeutic targets and drug treatments, addressing gaps in traditional discovery techniques that have struggled with these challenging conditions.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Precision BioSciences, founded in 2006, is a biotechnology company headquartered in Durham, North Carolina. It specializes in genome editing, developing therapeutic products using its proprietary ARCUS technology. The company focuses on creating allogeneic CAR T immunotherapies to treat cancers like acute lymphoblastic leukemia and non-hodgkin lymphoma, as well as genetic disorders.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Spring Discovery, Inc. is a biotechnology company based in Palo Alto, California, that specializes in the development of a machine learning-based drug discovery platform. This platform is designed to expedite the identification of therapies targeting the biological processes of aging and related diseases. By focusing on the underlying mechanisms of aging, Spring Discovery aims to uncover new treatments for various age-related conditions, including cardiovascular and neurodegenerative diseases. The company's innovative approach seeks to enhance healthy lifespans and improve the quality of life for the aging population.

Precision BioSciences, founded in 2006, is a biotechnology company headquartered in Durham, North Carolina. It specializes in genome editing, developing therapeutic products using its proprietary ARCUS technology. The company focuses on creating allogeneic CAR T immunotherapies to treat cancers like acute lymphoblastic leukemia and non-hodgkin lymphoma, as well as genetic disorders.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Navitor Pharmaceuticals is a biopharmaceutical company developing targeted therapies for various diseases by modulating mTORC1 activity. Founded in 2009, the company is headquartered in Cambridge, Massachusetts.